Company
Cann Global Limited
Headquarters: Sydney, NSW, Australia
CEO: Mr. Sholom Dovber Feldman
Market Cap
A$5.6 Million
AUD as of Jan. 1, 2024
US$3.8 Million
Cann Global Limited Categories
Australia Healthcare Drug Manufacturers—Specialty & GenericAustralia Healthcare Australia Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Cann Global Limited operates in medicinal cannabis and hemp food industries in Australia and internationally. The company operates through Hemp and Medical Cannabis Products, and Mining Exploration and Evaluation segments. It grows and cultivates hemp and medical cannabis products; and provides plant-based food and skincare products. The company also engages in the exploration and development of bauxite. In addition, it holds interests in the South Johnstone Project located in Queensland. The company was formerly known as Queensland Bauxite Limited and changed its name to Cann Global Limited in January 2019. Cann Global Limited was incorporated in 2007 and is based in Sydney, Australia.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Cann Global Limited has the following listings and related stock indices.
Stock: ASX: CGB wb_incandescent